Does IntraBio disclose revenue from AQNEURSA?

No. As of a January 21, 2026 FiercePharma report, IntraBio has not publicly disclosed sales figures for AQNEURSA despite the drug being FDA-approved since September 24, 2024, even as rival Zevra Therapeutics discloses public enrollment metrics for its competing NPC drug.

Who is IntraBio's biggest competitor?

Zevra Therapeutics. Its drug Miplyffa (arimoclomol) won FDA approval within days of IntraBio's AQNEURSA in September 2024 for the same Niemann-Pick type C indication, and Zevra publicly reported 137 prescription enrollment forms as of Q3 2024, per FiercePharma.

Could AI replace IntraBio's drug business?

Unlikely. IntraBio's value rests on FDA and EMA approvals, orphan-drug exclusivity, and NEJM-published Phase 3 trial data for AQNEURSA (approved September 24, 2024), none of which a generative AI model can substitute for or replicate.

Is IntraBio planning an IPO?

It's a live option but no timeline exists. A 2022 EY case study noted IntraBio engaged EY finance-transformation services partly to prepare for potential future IPO readiness, while the company remains privately, venture-backed as of 2026.

What is IntraBio's next major catalyst?

The FDA's PDUFA decision on September 19, 2026, for AQNEURSA's supplemental NDA expanding its label to Ataxia-Telangiectasia under Priority Review, following the March 2026 filing, per a June 7, 2026 BioSpace release.

Who owns and runs IntraBio?

IntraBio is privately held and founder-led. Mallory Factor founded the company in 2015 and serves as executive chairman (also referenced as President and CEO in a July 2026 release), with Jim Meyers cited elsewhere as CEO.

United States · United States

IntraBio

Biotech selling AQNEURSA, an FDA-approved oral therapy for the rare disease Niemann-Pick type C.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from September 19, 2026 · Every call on the record Checkpoint: FDA PDUFA decision on AQNEURSA for Ataxia-Telangiectasia (Priority Review)

The call

IntraBio holds real regulatory protection in a tiny disease market but stays silent on sales while its same-week rival Zevra publishes numbers.

IntraBio develops treatments for three ultra-rare neurological diseases (NPC, A-T, and CACNA1A) using a single molecule. The company has legal shields like FDA approval, patent protection, and exclusive rights that make it hard for big pharmaceutical companies to quickly copy its work, and it has published research backing its science. However, a rival company called Zevra Therapeutics launched a competing drug around the same time IntraBio's main product got approved, and Zevra has publicly shared patient enrollment numbers while IntraBio has shared zero sales figures, which suggests IntraBio might be losing the sales race. The biggest thing to watch is whether IntraBio can prove it is actually selling its drug better than Zevra's competing product, plus whether a regulatory decision in September 2026 for a second disease indication goes its way.

Why

AI pressure: None apparent. AI drug-discovery labs are not yet fielding rival small molecules for this ultra-rare, three-indication niche. Could AI do the core job? Unlikely.

Bigger players: Zevra Therapeutics (Miplyffa). Zevra's Miplyffa won FDA approval for the same NPC patients within days of AQNEURSA and now publishes enrollment counts IntraBio does not match. Could a giant copy it? No, they are blocked.

What protects it. FDA and EMA approvals, orphan-drug exclusivity, NEJM trial data, and a 27-patent estate make copying AQNEURSA slow and costly.

What would change this call

FDA PDUFA decision on AQNEURSA for Ataxia-Telangiectasia due September 19, 2026. Approval would expand IntraBio's indications; rejection would remove a key growth catalyst.
IntraBio discloses AQNEURSA sales or patient uptake figures for NPC. Would show whether IntraBio is gaining or losing ground against Zevra's Miplyffa in the same market.
Zevra publishes updated Miplyffa enrollment or sales figures beyond the 137 forms cited. Growing Zevra numbers alongside IntraBio silence would confirm IntraBio is falling behind commercially.

Key numbers

AQNEURSA won FDA approval for NPC (2024-09-24)
EU marketing authorization granted for AQNEURSA (2026-01-21)
Zevra reports 137 Miplyffa enrollment forms (2024-Q3)

Named risks

No public revenue disclosure for AQNEURSA while direct rival Zevra publishes enrollment metrics. Severity: high
Binary FDA PDUFA outcome on September 19, 2026 for A-T label expansion. Severity: high
Entire pipeline concentrated in one molecule across NPC, A-T, and CACNA1A indications. Severity: medium
Ultra-rare disease population limits total addressable market and revenue ceiling. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Zevra Therapeutics	contesting	Miplyffa approved days after AQNEURSA in Sept 2024; Zevra discloses 137 enrollment forms while IntraBio stays silent on sales as of Jan 2026
Actelion/Johnson and Johnson (miglustat, Zavesca)	contesting	EU label requires co-administration with miglustat in most AQNEURSA patients per EMA, July 2025, keeping the incumbent embedded in treatment

Questions people ask

Does IntraBio disclose revenue from AQNEURSA?: No. As of a January 21, 2026 FiercePharma report, IntraBio has not publicly disclosed sales figures for AQNEURSA despite the drug being FDA-approved since September 24, 2024, even as rival Zevra Therapeutics discloses public enrollment metrics for its competing NPC drug.
Who is IntraBio's biggest competitor?: Zevra Therapeutics. Its drug Miplyffa (arimoclomol) won FDA approval within days of IntraBio's AQNEURSA in September 2024 for the same Niemann-Pick type C indication, and Zevra publicly reported 137 prescription enrollment forms as of Q3 2024, per FiercePharma.
Could AI replace IntraBio's drug business?: Unlikely. IntraBio's value rests on FDA and EMA approvals, orphan-drug exclusivity, and NEJM-published Phase 3 trial data for AQNEURSA (approved September 24, 2024), none of which a generative AI model can substitute for or replicate.
Is IntraBio planning an IPO?: It's a live option but no timeline exists. A 2022 EY case study noted IntraBio engaged EY finance-transformation services partly to prepare for potential future IPO readiness, while the company remains privately, venture-backed as of 2026.
What is IntraBio's next major catalyst?: The FDA's PDUFA decision on September 19, 2026, for AQNEURSA's supplemental NDA expanding its label to Ataxia-Telangiectasia under Priority Review, following the March 2026 filing, per a June 7, 2026 BioSpace release.
Who owns and runs IntraBio?: IntraBio is privately held and founder-led. Mallory Factor founded the company in 2015 and serves as executive chairman (also referenced as President and CEO in a July 2026 release), with Jim Meyers cited elsewhere as CEO.

Timeline

2026-06-07IntraBio files EMA variation application to extend AQNEURSA to Ataxia-Telangiectasia
2026-05-20Regulators in US, UK, EU, Switzerland authorize Phase III trial for CACNA1A disorders
2026-03-25IntraBio submits sNDA for AQNEURSA in Ataxia-Telangiectasia with Priority Review
2026-01-21European Commission grants full marketing authorization for AQNEURSA in NPC
2025-11-01EU regulators reaffirm levacetylleucine does not qualify for new active substance status
2025-07-25EMA CHMP recommends EU approval of AQNEURSA for NPC
2024-09-24FDA approves AQNEURSA for NPC, days after rival Zevra's Miplyffa approval
2024-02-01Phase 3 pivotal trial results for AQNEURSA in NPC published in NEJM
2023-04-05IntraBio closes $15 million Series C funding round

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.